A Phase 3 interventional study of Inclisiran and Behavioural Support in Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents and Elevated Low Density Lipoprotein Cholesterol, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.
Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 5th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 30–50
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 892 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 401 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Atherosclerosis by Novartis: 4 open now, 10 under way, 3 of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 27 studies in Atherosclerosis by Novartis, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 8th registered.
Novartis’s Atherosclerosis studies by the year they started, since 2006.
4 of the studies testing inclisiran in Atherosclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing inclisiran in Atherosclerosis, from their registry updates:
Among Novartis’s 27 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK
Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol (LDL-cholesterol) in the blood. Inclisiran works in a way that makes the liver produce less of a substance called 'PCSK9'. PCSK9 reduces the ability of the liver to remove LDL-cholesterol from the blood. By lowering the production of PCSK9, Inclisiran leads to more LDL-cholesterol being removed by the liver from the blood, thereby reducing LDL-cholesterol overall.
A phase IIIb, multicenter, randomized controlled study to evaluate the implementation, preference, and utility for administration of inclisiran sodium in participants on established lipid lowering medication or, have been recommended lipid lowering therapy by their healthcare provider but are unable to tolerate treatment, with elevated low density lipoprotein cholesterol (LDL-C) in a primary care population. This study was an implementation research study that utilized implementation science methodology and use of the electronic medical record (EMR).
Using implementation science methodology, the study intended to assess the effect of 9 months treatment with inclisiran with/without behavioural support, compared to standard of care + behavioural support, on LDL-C reduction, total lipid profile, assessments of patient and healthcare professional (HCP) satisfaction, health-care resource utilization and healthcare service process evaluation.
The primary focus of this study was implementation and 'transactability' - how to organize, deliver and maintain an innovative treatment for Atherosclerotic Cardiovascular Disease (ASCVD) in a primary care setting in a sustainable way.
Patients taking part in the study were randomised to one of three groups:
Participants who were randomized to Inclisiran or Inclisiran + BS received one injection of inclisiran on Day 1 and a second injection of inclisiran on Day 90.
Participants in Control + BS and Inclisiran + BS received a monthly telephone call from a health advisor, providing support to enable participants to make positive behaviour changes to reduce their cardiovascular risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).
Behavioral: Behavioural Support · Drug: Background lipid lowering therapy
Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).
Drug: Inclisiran · Drug: Background lipid lowering therapy
Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.
Drug: Inclisiran · Behavioral: Behavioural Support · Drug: Background lipid lowering therapy
Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
Percentage Change in LDL-C From Baseline to Day 270
Change in Low Density Lipoprotein Cholesterol (LDL-C) after 270 days of treatment in adults on established lipid lowering medication or who have been recommended lipid lowering therapy by their health care provider but are unable to tolerate treatment, regardless of treatment discontinuation for any reason and regardless of unforeseen change in the concomitant lipid lowering therapy. Multiple imputation is used to impute missing data using a washout model.
Time frame: Baseline, Day 270
Number of Participants Interviewed for CFIR Analysis.
To identify the need to support the implementation of inclisiran in the real world, a framework was drawn known as the Consolidated Framework for Implementation Research (CFIR). Patients who received inclisiran were interviewed to understand their experience with the program and to obtain a comprehensive understanding, with or without behavioural support. These patients were interviewed on various aspects of their experience related to their high cholesterol management, trial participation, inclisiran injections, attending appointments, and if applicable their experience with the behavioural support programme. These interviews were not set up in a way that allow numerical analysis. The process evaluation was conducted by Manchester University.
Time frame: Day 270
Patient Reported Outcomes: CSQ-8 Total Score After Treatment
The Client Satisfaction Questionnaire (CSQ)-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction.
Time frame: Day 90
Patient Reported Outcomes: CSQ-8 Total Score Between Inclisiran Arms
The CSQ-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction. This secondary outcome only analysed data of the two Inclisiran arms, by considering the Inclisiran only arm as the control group. The standard error for Least Square Mean could change because dropping a treatment arm affects the estimation of treatment effects and the variability of data.
Time frame: Day 90
Change From Baseline to Day 90 in Total PAM Score
The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. A standardised spreadsheet in excel is used to score the PAM. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated.
Time frame: Baseline, Day 90
Change From Baseline to Day 90 in Total PAM Score Between Inclisiran Arms
The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated. This outcome only analysed data of the two inclisiran arms, by considering the Inclisiran only arm as the control group. In an ANCOVA model, the Least Squares Means and corresponding Standard Error could change because the removal of a treatment group affects the estimation of the treatment effects and the adjustment for the covariate(s).
Time frame: Baseline, Day 90
Measures of Adherence to Cardiovascular Disease Self-management Using the Validated Patient Activation Measure (PAM) Questionnaire.
The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100. The continuous PAM scores are then categorised into 4 levels: Level 1 - disengaged and overwhelmed; Level 2 - become aware but still struggling; Level 3 - taking action; Level 4 - maintaining behaviors and pushing further.
Time frame: Baseline, Day 90
The study was conducted at 17 primary care centres with a network of research ready General Practitioners across Greater Manchester, United Kingdom.
| Milestone | Inclisiran | Inclisiran + BS | Control+ BS |
|---|---|---|---|
| Started | 298 | 297 | 297 |
| Full analysis set | 297 | 297 | 297 |
| Safety set | 273 | 281 | 290 |
| Completed | 248 | 252 | 234 |
| Not completed | 50 | 45 | 63 |
| Withdrew: Adverse event | 2 | 3 | 3 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 6 | 6 |
| Withdrew: Non-compliance with study drug | 0 | 4 | 1 |
| Withdrew: Participant decision | 20 | 19 | 26 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Protocol violation | 4 | 3 | 7 |
| Withdrew: Withdrawal by subject | 13 | 9 | 20 |
| Withdrew: Mis-randomized | 1 | 0 | 0 |
Change in Low Density Lipoprotein Cholesterol (LDL-C) after 270 days of treatment in adults on established lipid lowering medication or who have been recommended lipid lowering therapy by their health care provider but are unable to tolerate treatment, regardless of treatment discontinuation for any reason and regardless of unforeseen change in the concomitant lipid lowering therapy. Multiple imputation is used to impute missing data using a washout model.
| percent change from baseline in LDL-C | Inclisiran | Inclisiran + BS | Control+ BS |
|---|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 270 | -37.3 ± 2.29 | -37.6 ± 2.33 | -5.4 ± 2.34 |
To identify the need to support the implementation of inclisiran in the real world, a framework was drawn known as the Consolidated Framework for Implementation Research (CFIR). Patients who received inclisiran were interviewed to understand their experience with the program and to obtain a comprehensive understanding, with or without behavioural support. These patients were interviewed on various aspects of their experience related to their high cholesterol management, trial participation, inclisiran injections, attending appointments, and if applicable their experience with the behavioural support programme. These interviews were not set up in a way that allow numerical analysis. The process evaluation was conducted by Manchester University.
| Participants | Inclisiran | Inclisiran + BS |
|---|---|---|
| Number of Participants Interviewed for CFIR Analysis. | 28 | 28 |
The Client Satisfaction Questionnaire (CSQ)-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction.
| score on a scale | Inclisiran | Inclisiran + BS | Control+ BS |
|---|---|---|---|
| Patient Reported Outcomes: CSQ-8 Total Score After Treatment | 30.1 ± 0.24 | 30.1 ± 0.24 | 28.7 ± 0.30 |
The CSQ-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction. This secondary outcome only analysed data of the two Inclisiran arms, by considering the Inclisiran only arm as the control group. The standard error for Least Square Mean could change because dropping a treatment arm affects the estimation of treatment effects and the variability of data.
| score on a scale | Inclisiran + BS | Inclisiran |
|---|---|---|
| Patient Reported Outcomes: CSQ-8 Total Score Between Inclisiran Arms | 30.1 ± 0.23 | 30.1 ± 0.23 |
The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. A standardised spreadsheet in excel is used to score the PAM. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated.
| score on a scale | Inclisiran | Inclisiran + BS | Control+ BS |
|---|---|---|---|
| Change From Baseline to Day 90 in Total PAM Score | 2.4 ± 1.18 | 2.7 ± 1.14 | 1.4 ± 2.01 |
The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated. This outcome only analysed data of the two inclisiran arms, by considering the Inclisiran only arm as the control group. In an ANCOVA model, the Least Squares Means and corresponding Standard Error could change because the removal of a treatment group affects the estimation of the treatment effects and the adjustment for the covariate(s).
| score on a scale | Inclisiran + BS | Inclisiran |
|---|---|---|
| Change From Baseline to Day 90 in Total PAM Score Between Inclisiran Arms | 2.6 ± 1.17 | 2.3 ± 1.21 |
The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100. The continuous PAM scores are then categorised into 4 levels: Level 1 - disengaged and overwhelmed; Level 2 - become aware but still struggling; Level 3 - taking action; Level 4 - maintaining behaviors and pushing further.
| Participants | Inclisiran | Inclisiran + BS | Control+ BS |
|---|---|---|---|
| Level 1 (Disengaged and overwhelmed) at Baseline | 13 | 20 | 7 |
| Level 2 (Become aware but still struggling) at Baseline | 47 | 50 | 15 |
| Level 3 (Taking action) at Baseline | 61 | 75 | 36 |
| Level 4 (Maintaining behaviors and pushing further) at Baseline | 48 | 44 | 21 |
| Missing PAM scores at baseline | 128 | 108 | 218 |
| Level 1 (Disengaged and overwhelmed) at Day 90 | 9 | 8 | 6 |
| Level 2 (Become aware but still struggling) Day 90 | 37 | 38 | 23 |
| Level 3 (Taking action) at Day 90 | 63 | 64 | 46 |
| Level 4 (Maintaining behaviors and pushing further) at Day 90 | 56 | 47 | 33 |
| Missing PAM scores at Day 90 | 132 | 140 | 189 |
Collected over Adverse events were reported from first dose of study treatment until end of study visit plus 30 days post treatment, up to a maximum duration of 300 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran | 2/273 (0.7%) | 24/273 (8.8%) | 3/273 (1.1%) |
| Inclisiran + BS | 0/281 (0%) | 36/281 (12.8%) | 2/281 (0.7%) |
| Control + BS | 0/290 (0%) | 28/290 (9.7%) | 0/290 (0%) |
| Total | 2/844 (0.2%) | 88/844 (10.4%) | 5/844 (0.6%) |
| Event | Inclisiran | Inclisiran + BS | Control + BS | Total |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 2/273 | 5/281 | 0/290 | 7/844 |
| PneumoniaInfections and infestations | 4/273 | 1/281 | 1/290 | 6/844 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 3/273 | 1/281 | 2/290 | 6/844 |
| Suicidal ideationPsychiatric disorders | 2/273 | 0/281 | 1/290 | 3/844 |
| Acute kidney injuryRenal and urinary disorders | 2/273 | 2/281 | 0/290 | 4/844 |
| DiverticulitisInfections and infestations | 0/273 | 2/281 | 0/290 | 2/844 |
| Urinary tract infectionInfections and infestations | 1/273 | 2/281 | 0/290 | 3/844 |
| UrosepsisInfections and infestations | 1/273 | 2/281 | 0/290 | 3/844 |
| Acute myocardial infarctionCardiac disorders | 1/273 | 1/281 | 2/290 | 4/844 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/273 | 0/281 | 0/290 | 1/844 |
| Event | Inclisiran | Inclisiran + BS | Control + BS | Total |
|---|---|---|---|---|
| Injection site rashGeneral disorders | 1/273 | 0/281 | 0/290 | 1/844 |
| Back painMusculoskeletal and connective tissue disorders | 1/273 | 0/281 | 0/290 | 1/844 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/273 | 0/281 | 0/290 | 1/844 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/273 | 0/281 | 0/290 | 1/844 |
| DizzinessNervous system disorders | 0/273 | 1/281 | 0/290 | 1/844 |
| RashSkin and subcutaneous tissue disorders | 0/273 | 1/281 | 0/290 | 1/844 |
Baseline Participants are based on the Full Analysis Set (FAS) population, as primary and secondary analysis are based on the FAS
| Age, Continuous(Years) | Inclisiran | Inclisiran + BS | Control+ BS | Total |
|---|---|---|---|---|
| Mean | 66.0 ± 9.27 | 65.8 ± 9.71 | 66.7 ± 9.45 | 66.2 ± 9.47 |
| Sex: Female, Male(Participants) | Inclisiran | Inclisiran + BS | Control+ BS | Total |
|---|---|---|---|---|
| Female | 170 | 174 | 180 | 524 |
| Male | 127 | 123 | 117 | 367 |
| Race/Ethnicity, Customized(Participants) | Inclisiran | Inclisiran + BS | Control+ BS | Total |
|---|---|---|---|---|
| Asian | 11 | 3 | 9 | 23 |
| Black | 1 | 0 | 5 | 6 |
| Mixed | 1 | 3 | 1 | 5 |
| White | 281 | 289 | 278 | 848 |
| Other | 3 | 2 | 4 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2021 to primary completion in Jan 2023, 18 months.
Results were first posted in Mar 2024, 1 year 2 months after primary completion.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 18 months is below that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran